{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:17:55Z","timestamp":1787242675373,"version":"build-2736575974"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T00:00:00Z","timestamp":1734998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T00:00:00Z","timestamp":1734998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"DOI":"10.1007\/s11255-024-04344-7","type":"journal-article","created":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T09:36:52Z","timestamp":1735033012000},"page":"1433-1440","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Application of extended immunotherapy in advanced clear cell renal cell carcinoma treated with first-line combination of immune-checkpoint inhibitor and tyrosine kinase inhibitor"],"prefix":"10.1007","volume":"57","author":[{"given":"Qian","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiyu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jindong","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junru","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinge","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangxi","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenhua","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengfei","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,24]]},"reference":[{"issue":"6","key":"4344_CR1","first-page":"507","volume":"67","author":"PC Barata","year":"2017","unstructured":"Barata PC, Rini BI (2017) Treatment of renal cell carcinoma: current status and future directions [J]. CA: A Cancer J Clin 67(6):507\u2013524","journal-title":"CA: A Cancer J Clin"},{"key":"4344_CR2","first-page":"caac.21834","volume":"2024","author":"F Bray","year":"2022","unstructured":"Bray F, Laversanne M, Sung H, Global cancer statistics et al (2022) GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA: A Cancer J Clin 2024:caac.21834","journal-title":"CA: A Cancer J Clin"},{"issue":"3","key":"4344_CR3","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.eururo.2014.10.002","volume":"67","author":"A Znaor","year":"2015","unstructured":"Znaor A, Lortet-Tieulent J, Laversanne M et al (2015) International variations and trends in renal cell carcinoma incidence and mortality [J]. European Urol 67(3):519\u2013530","journal-title":"European Urol"},{"issue":"6","key":"4344_CR4","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.eururo.2021.03.016","volume":"80","author":"IB Riaz","year":"2021","unstructured":"Riaz IB, He H, Ryu AJ et al (2021) A living, interactive systematic review and network meta-analysis of first-line treatment of metastatic renal cell carcinoma[J]. European Urol 80(6):712\u2013723","journal-title":"European Urol"},{"issue":"12","key":"4344_CR5","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","volume":"380","author":"BI Rini","year":"2019","unstructured":"Rini BI, Plimack ER, Stus V et al (2019) Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma[J]. New England J Med 380(12):1116\u20131127","journal-title":"New England J Med"},{"key":"4344_CR6","unstructured":"European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update - PubMed[EB\/OL]. \/2024\u201304\u201310. https:\/\/pubmed.ncbi.nlm.nih.gov\/35346519\/."},{"issue":"14","key":"4344_CR7","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","volume":"378","author":"RJ Motzer","year":"2018","unstructured":"Motzer RJ, Tannir NM, McDermott DF et al (2018) Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma[J]. New England J Med 378(14):1277\u20131290","journal-title":"New England J Med"},{"issue":"1","key":"4344_CR8","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.euf.2019.10.010","volume":"6","author":"N Singla","year":"2020","unstructured":"Singla N, Freifeld Y, Ghandour RA et al (2020) Rational approaches to treatment duration with immunotherapy in metastatic renal cell carcinoma[J]. Eur Urol Focus 6(1):31\u201333","journal-title":"Eur Urol Focus"},{"issue":"11","key":"4344_CR9","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/s41571-020-0399-6","volume":"17","author":"C Robert","year":"2020","unstructured":"Robert C, Marabelle A, Herrscher H et al (2020) Immunotherapy discontinuation - how, and when? Data from melanoma as a paradigm [J]. Nature Rev Clin Oncol 17(11):707\u2013715","journal-title":"Nature Rev Clin Oncol"},{"issue":"33","key":"4344_CR10","doi-asserted-by":"publisher","first-page":"3863","DOI":"10.1200\/JCO.20.00131","volume":"38","author":"DM Waterhouse","year":"2020","unstructured":"Waterhouse DM, Garon EB, Chandler J et al (2020) Continuous versus 1-year fixed-duration nivolumab in previously treated advanced non-small-cell lung cancer: checkmate 153[J]. J Clin Oncol 38(33):3863\u20133873","journal-title":"J Clin Oncol"},{"key":"4344_CR11","doi-asserted-by":"publisher","first-page":"862","DOI":"10.3389\/fonc.2020.00862","volume":"10","author":"A Friedlaender","year":"2020","unstructured":"Friedlaender A, Kim C, Addeo A (2020) Rethinking the optimal duration of immune checkpoint inhibitors in non-small cell lung cancer throughout the COVID-19 pandemic[J]. Front Oncol 10:862","journal-title":"Front Oncol"},{"issue":"18","key":"4344_CR12","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1200\/JCO.2014.58.1041","volume":"33","author":"DF McDermott","year":"2015","unstructured":"McDermott DF, Drake CG, Sznol M et al (2015) Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab [J]. Journal of Clin Oncol 33(18):2013\u20132020","journal-title":"Journal of Clin Oncol"},{"issue":"10","key":"4344_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003473","volume":"9","author":"A Tzeng","year":"2021","unstructured":"Tzeng A, Tzeng TH, Ornstein MC (2021) Treatment-free survival after discontinuation of immune checkpoint inhibitors in metastatic renal cell carcinoma: a systematic review and meta-analysis[J]. J Immunother Cancer 9(10):e003473","journal-title":"J Immunother Cancer"},{"issue":"2","key":"4344_CR14","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)[J]. Eur J Cancer 45(2):228\u2013247","journal-title":"Eur J Cancer"},{"issue":"3","key":"4344_CR15","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1200\/JCO.1984.2.3.187","volume":"2","author":"CC Schag","year":"1984","unstructured":"Schag CC, Heinrich RL, Ganz PA (1984) Karnofsky performance status revisited: reliability, validity, and guidelines [J]. J Clin Oncol 2(3):187\u2013193","journal-title":"J Clin Oncol"},{"issue":"14","key":"4344_CR16","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","volume":"384","author":"R Motzer","year":"2021","unstructured":"Motzer R, Alekseev B, Rha S-Y et al (2021) Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma[J]. New England J Med 384(14):1289\u20131300","journal-title":"New England J Med"},{"issue":"9","key":"4344_CR17","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa2026982","volume":"384","author":"TK Choueiri","year":"2021","unstructured":"Choueiri TK, Powles T, Burotto M et al (2021) Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma[J]. New England J Med 384(9):829\u2013841","journal-title":"New England J Med"},{"issue":"2","key":"4344_CR18","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.annonc.2023.09.3108","volume":"35","author":"XQ Yan","year":"2024","unstructured":"Yan XQ, Ye MJ, Zou Q et al (2024) 2024 Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study[J]. Annals Oncol 35(2):190\u2013199","journal-title":"Annals Oncol"},{"issue":"12","key":"4344_CR19","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/S1470-2045(20)30436-8","volume":"21","author":"T Powles","year":"2020","unstructured":"Powles T, Plimack ER, Souli\u00e8res D et al (2020) Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial[J]. Lancet Oncol 21(12):1563\u20131573","journal-title":"Lancet Oncol"},{"issue":"11","key":"4344_CR20","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1200\/JCO.23.01569","volume":"42","author":"RJ Motzer","year":"2024","unstructured":"Motzer RJ, Porta C, Eto M et al (2024) Lenvatinib plus pembrolizumab versus sunitinib in first-line treatment of advanced renal cell carcinoma: final prespecified overall survival analysis of CLEAR, a phase III study[J]. J Clin Oncol 42(11):1222\u20131228","journal-title":"J Clin Oncol"},{"key":"4344_CR21","unstructured":"ASCO 2023: Pembrolizumab + Axitinib Versus Sunitinib as First-Line Therapy for Advanced Clear Cell RCC: 5-Year Analysis of KEYNOTE-426[EB\/OL]. \/2024\u201304\u201313. https:\/\/www.urotoday.com\/conference-highlights\/asco-2023\/asco-2023-kidney-cancer\/144965-asco-2023-pembrolizumab-axitinib-versus-sunitinib-as-first-line-therapy-for-advanced-clear-cell-rcc-5-year-analysis-of-keynote-426.html."},{"issue":"10","key":"4344_CR22","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1016\/j.jtho.2021.05.001","volume":"16","author":"RS Herbst","year":"2021","unstructured":"Herbst RS, Garon EB, Kim D-W et al (2021) Five year survival update from KEYNOTE-010: pembrolizumab versus docetaxel for previously treated, programmed death-ligand 1-positive advanced NSCLC[J]. J Thoracic Oncol 16(10):1718\u20131732","journal-title":"J Thoracic Oncol"},{"issue":"9","key":"4344_CR23","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/S1470-2045(19)30388-2","volume":"20","author":"C Robert","year":"2019","unstructured":"Robert C, Ribas A, Schachter J et al (2019) Five-year follow-up of nivolumab in previously treated advanced non\u2013small-cell lung cancer: results from the CA209\u2013003 study[J]. Lancet Oncol 20(9):1239\u20131251","journal-title":"Lancet Oncol"},{"issue":"17","key":"4344_CR24","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1200\/JCO.2017.77.0412","volume":"36","author":"S Gettinger","year":"2018","unstructured":"Gettinger S, Horn L, Jackman D et al (2018) Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study[J]. J Clin Oncol 36(17):1675\u20131684","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"4344_CR25","doi-asserted-by":"publisher","first-page":"9539","DOI":"10.1200\/JCO.2017.35.15_suppl.9539","volume":"35","author":"Y Jansen","year":"2017","unstructured":"Jansen Y, Rozeman EA, Foppen MG et al (2017) Real life outcome of advanced melanoma patients who discontinue pembrolizumab (PEMBRO) in the absence of disease progression[J]. J Clin Oncol 35(15_suppl):9539\u20139539","journal-title":"J Clin Oncol"},{"issue":"389","key":"4344_CR26","doi-asserted-by":"publisher","first-page":"eaal3604","DOI":"10.1126\/scitranslmed.aal3604","volume":"9","author":"SP Arlauckas","year":"2017","unstructured":"Arlauckas SP, Garris CS, Kohler RH et al (2017) In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy[J]. Sci Trans Med 9(389):eaal3604","journal-title":"Sci Trans Med"},{"issue":"28","key":"4344_CR27","doi-asserted-by":"publisher","first-page":"3617","DOI":"10.1038\/onc.2014.314","volume":"34","author":"P Ramos","year":"2015","unstructured":"Ramos P, Bentires-Alj M (2015) Mechanism-based cancer therapy: resistance to therapy, therapy for resistance[J]. Oncogene 34(28):3617\u20133626","journal-title":"Oncogene"},{"issue":"17","key":"4344_CR28","doi-asserted-by":"publisher","first-page":"4992","DOI":"10.1158\/1078-0432.CCR-16-3066","volume":"23","author":"CS Baik","year":"2017","unstructured":"Baik CS, Rubin EH, Forde PM et al (2017) Immuno-oncology clinical trial design: limitations, challenges, and opportunities[J]. Clin Cancer Res 23(17):4992\u20135002","journal-title":"Clin Cancer Res"},{"issue":"17","key":"4344_CR29","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1200\/JCO.2017.75.6270","volume":"36","author":"C Robert","year":"2018","unstructured":"Robert C, Ribas A, Hamid O et al (2018) Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma[J]. J Clin Oncol 36(17):1668\u20131674","journal-title":"J Clin Oncol"},{"issue":"4","key":"4344_CR30","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1093\/annonc\/mdz011","volume":"30","author":"O Hamid","year":"2019","unstructured":"Hamid O, Robert C, Daud A et al (2019) Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001[J]. Annals Oncol 30(4):582\u2013588","journal-title":"Annals Oncol"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-024-04344-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-024-04344-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-024-04344-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T09:59:28Z","timestamp":1744797568000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-024-04344-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,24]]},"references-count":30,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["4344"],"URL":"https:\/\/doi.org\/10.1007\/s11255-024-04344-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5416848\/v1","asserted-by":"object"}]},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,24]]},"assertion":[{"value":"8 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that the study is conducted without any financial relationship and without competing conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"We have secured the informed consent of all participants involved in the study and all procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee (name of institute\/committee) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}